{"filing":{"accession_number":"0001645113-26-000053","cik":"0001645113","ticker":"NVCR","company_name":"NovoCure Ltd","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"nvcr-20260618.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000053/nvcr-20260618.htm"},"events":[{"id":11684,"run_id":10267,"accession_number":"0001645113-26-000053","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"NovoCure announced topline results from its Phase 3 TRIDENT trial, a pivotal clinical study evaluating TTFields therapy timing in glioblastoma treatment. The trial did not meet its primary endpoint of demonstrating statistically significant overall survival improvement for early initiation (HR 0.953; p=0.519), which is material to investors assessing the company's pipeline and commercial prospects. While this is clinical trial data rather than a traditional earnings release, the negative primary endpoint outcome for a Phase 3 pivotal trial is a material event affecting investor assessment of the registrant's development programs and future revenue potential.","company_name":"NovoCure Ltd","ticker":"NVCR","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8333,"accession_number":"0001645113-26-000053","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"NovoCure announced topline results from its Phase 3 TRIDENT trial, a pivotal clinical study evaluating TTFields therapy timing in glioblastoma treatment. The trial did not meet its primary endpoint of demonstrating statistically significant overall survival improvement for early initiation (HR 0.953; p=0.519), which is material to investors assessing the company's pipeline and commercial prospects. While this is clinical trial data rather than a traditional earnings release, the negative primary endpoint outcome for a Phase 3 pivotal trial is a material event affecting investor assessment of the registrant's development programs and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:01:07.112195+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8333,"accession_number":"0001645113-26-000053","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"NovoCure announced topline results from its Phase 3 TRIDENT trial, a pivotal clinical study evaluating TTFields therapy timing in glioblastoma treatment. The trial did not meet its primary endpoint of demonstrating statistically significant overall survival improvement for early initiation (HR 0.953; p=0.519), which is material to investors assessing the company's pipeline and commercial prospects. While this is clinical trial data rather than a traditional earnings release, the negative primary endpoint outcome for a Phase 3 pivotal trial is a material event affecting investor assessment of the registrant's development programs and future revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:01:07.112195+00:00","company_name":"NovoCure Ltd","ticker":"NVCR","filing_date":"2026-06-18"}]}